SCIENCE

Our Therapeutic Leadership

For 35 years, Gilead has discovered, developed and delivered innovative therapies in areas of great unmet need. We helped transform HIV from a fatal disease to one that can be well managed, and we’ve helped cure millions of people with hepatitis C around the world. Our decades of research in emerging viruses allowed us to deliver the first conditionally approved treatment for COVID-19. And together with Kite, a Gilead Company, which is focused on cell therapy, we’re making an impact in multiple types of cancer.

Known for our commitment to innovation and access, we are poised to meet our ambition, set in 2019, to deliver 10+ transformative therapies by 2030.

Inside Virology at Gilead

What We’ve Accomplished

As a leader and pioneer in antiviral development, we helped transform HIV from a fatal illness to a preventable chronic condition. We introduced the first HIV single tablet treatment regimen and continue to improve safety, convenience and efficacy in treatment and prevention options. In hepatitis, we developed a cure for hepatitis C, and our therapies helped transform hepatitis B into a more manageable condition. And when the world needed us, we stepped up to deliver the first conditionally approved antiviral medicine to treat COVID-19.

These advances were possible thanks to our investment in world-class science, our deep connections with community partners and our long-standing commitment to expanding health equity.

Our Current Focus

Today, we’re building on our legacy in virology and providing long-acting options for HIV treatment while working together with community partners to help end the epidemic. At the same time, we're developing new treatments for chronic hepatitis B and D as we work toward the global elimination of hepatitis.

Looking Ahead

We won’t rest until the HIV epidemic has ended for everyone, everywhere. Ultimately, we're working to help develop cures for HIV and hepatitis B, while advancing our preparedness against potential infectious diseases.

At the same time, we recognize that medicines alone won’t lead to the healthier world we envision. We’re committed to working closely with partners to advance health equity and break down the barriers to care that fuel the spread of viruses and affect access to care.

Our work in Oncology

Innovation

We’re innovating with next-generation therapies, combinations and technologies to expand our oncology portfolio and bring more life to people with cancer. Over the past few years, Gilead and Kite have received eight indication approvals across more than 50 countries, expanding our oncology platform across major pathways, including cell therapies and medicines for difficult-to-treat metastatic cancers.

We refuse to accept that cancer can still take the ones we love, and we’re actively collaborating with the oncology community in pursuit of equitable access to cancer care.

Impact

We want to positively impact the lives of more than 500,000 people with cancer around the world by 2030.